Crossmark

Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease

Crossref DOI link: https://doi.org/10.1016/j.farma.2024.01.002

Published Print: 2025-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Poquet-Jornet, Jaime E.

Ibáñez-Sala, Inés

Garrigues-Pelufo, Teresa

Munilla-Das, Adrián

Valdivia-Pérez, Antonio

Carrera-Hueso, Francisco Javier
License Information

Text and Data Mining valid from 2025-03-01

Text and Data Mining valid from 2025-03-01

Version of Record valid from 2024-01-09
More Information

This article is maintained by: Elsevier

Article Title: Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease

Journal Title: Farmacia Hospitalaria

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.farma.2024.01.002

Content Type: article

Copyright: © 2024 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier España, S.L.U.